Efamol Limited

Other

Verronmay Limited

David F Horrobin

Julian Lieb

The invention relates to a method of skin treatment comprising the step of topically applying to skin affected by seborrheic dermatitis an amount of a composition comprising an excipient and from about 1% to 30% lithium ion, said amount being sufficient to reduce sebum production by said skin. The invention also relates to a method of skin treatment, which comprises the step of topically applying to skin affected by seborrheic dermatitis an amount of a composition comprising a topically acceptable excipient and an effective amount of a lithium salt.

Methods and compositions for the treatment of the skin

A composition of an effective amount of (a) .gamma.-linolenic acid and/or dihomo-.gamma.-linolenic acid, optionally in association with linoleic and if desired other fat acids, said acids being used if desired as physiologically functional derivatives thereof, in conjunction with (b) an effective amount of one or more of natural or synthetic carotenoids or retinoids having, or giving rise in the body to compounds having, Vitamin A activity when used in therapy of a condition in which enhancement of 1-series PG production, or more broadly influence of the 1-series/2-series PG balance in the body in favor of 1-series PGs is required.

Method for enhancement of 1-series PG production

The treatment of viral infections with a lithium salt and one of cytarabine or idoxuridine.

Anti-viral compositions

Topical pharmaceutical compositions for the treatment of lesions of the skin or mucous membranes containing a physiologically acceptable lithium salt together with at least one substance selected from substances capable of selectively increasing the in vivo level of E-series prostaglandins, substances capable of inhibiting cyclooxygenase enzyme, substances capable of inhibiting the formation of lipoxygenase products, and lysine.

Topical pharmaceutical compositions

The anti-viral effectiveness of conventional anti-viral agents such as acyclovir, idoxuridine, vidarabine etc. is enhanced by formulation or administration with a physiologically acceptable lithium salt.

Use of .gamma.-linolenic acid and related materials with (i) zinc, .beta.-lactam antibiotics or other materials enhancing physiological l-series PG synthesis and/or (ii) colchicine, Vinca alkaloids or other materials enhancing physiological synthesis of thromboxane A2, for treatment of malignant tumors susceptible to treatment with gamma-linolenic acid or dihomo-gamma-linolenic acid.

Pharmaceutical and dietary composition

A pharmaceutical composition comprises one or more essential fatty acids, for example, .gamma.-linolenic acid or dihomo-.gamma.-linolenic acid, in conjunction with rutin, troxerutin or other bioflavonoid. The composition is useful in the treatment of inflammation or defective T-lymphocyte function.

Method of treating defective T-lymphocyte function with rutin or

The anti-viral effectiveness of conventional anti-viral agents such as acylovir, idoxuridine, vidarabine etc. is enhanced by formulation or administration with a physiologically acceptable lithium salt.

A method of treatment of atopic disorders, including eczema, asthma, allergies (especially allergic rhinitis), migraine and disorders associated with atopy including Crohn's disease, ulcerative colitis, otitis media, nephrotic syndrome, or benign breast disease, or breast or other cancer, or diabetes, or alcoholism, with effective amounts of one or more of the metabolites of linoleic acid (GLA, DGLA, AA, 22:4n-6 or 22:5n-6) and one or more of the metabolites of .alpha.-linolenic acid (18:4n-3, 20:4n-3, 20:5n-3, 22:5n-3 or 22:6n-3) are administered as such or in the form of an ester, salt, amide or other derivative convertible in the body thereto alone or in an acceptable pharmaceutical carrier or diluent.

A method of treatment of atopic disorders, including eczema, asthma, allergies (especially allergic rhinitis), migraine and disorders associated with atopy including Crohn's disease, ulcerative colitis, otitis media, nephrotic syndrome, or benign breast disease, or breast or other cancer, or diabetes, or alcoholism, with effective amounts of one or more of the metabolites of linoleic acid (GLA, DGLA, AA, 22:4n-6 or 22:5n-6) and one or more of the metabolites of .alpha.-linolenic acid (18:4n-3), 20:4n-3, 20:5n-3, 22:5n-3 or 22:6n-3) are administered as such or in the form of an ester, salt, amide or other derivative convertible in the body thereto along or in an acceptable pharmaceutical carrier or diluent.

Composition and use of .gamma.-linolenic acid and related materials with ascorbic acid, or ethyl alcohol, or an opiate antagonist such as naloxone, nalorphine or levallorphan, for treating alcoholism or moderating the effects of taking alcohol.

Use of .gamma.-linolenic acid and related materials alone or with zinc or .beta.-lactam antibiotics to treat skin disorders.

Treatment for skin disorders

Use of .gamma.-linolenic acid and related materials alone or with zinc or .beta.-lactam antibiotics to treat menstrual disorders.

Treatment for menstrual disorders

Use of .gamma.-linolenic acid and related materials alone or with zinc or .beta.-lactam antibiotics to treat obesity.

Growing community of inventors

Montreal, Canada

David F Horrobin